The global vascular stents market continues to demonstrate strong growth momentum, driven by rising cases of cardiovascular diseases, an increasing preference for minimally invasive procedures, and advancements in stent technologies. Valued at US$10.7 billion in 2023, the market grew to US$11.4 billion in 2024 and is projected to expand at a CAGR of 6.5% from 2024 to 2029, reaching US$15.6 billion by 2029. This consistent rise highlights the market’s strong potential across developed and developing healthcare economies.

Download PDF Brochure

Market Overview and Growth Drivers

The expansion of the vascular stents market is primarily influenced by the increasing incidence of vascular diseases such as coronary artery disease (CAD), peripheral artery disease (PAD), and endovascular aortic aneurysms. The rising adoption of angioplasty procedures—driven by their high success rate and reduced recovery time—plays a key role in accelerating market demand.

Growing patient preference for minimally invasive surgeries, which offer reduced hospital stay, lower postoperative pain, and quicker rehabilitation, is further supporting the demand for vascular stents. Technological innovations such as next-generation drug-eluting stents, thinner strut designs, and enhanced biocompatible materials are transforming the cardiology landscape, encouraging wider adoption of stent-based interventions.

However, certain restraints continue to challenge market performance. The availability of alternative treatments such as open surgical procedures, along with increasing incidences of stent-related complications and product recalls, pose hurdles to consistent market expansion. Despite these challenges, emerging economies and the growing development of bioresorbable vascular scaffold stents (BVS) offer substantial opportunities for market players during the forecast period.

Mode of Delivery Analysis: Balloon-Expandable Stents Lead Growth

By mode of delivery, the vascular stents market is segmented into:

• Balloon-expandable stents
• Self-expanding stents

In 2023, balloon-expandable stents emerged as the fastest-growing segment. Their increased adoption is driven by the rising prevalence of coronary heart diseases and their inherent advantages over self-expanding stents. Balloon-expandable stents offer:

• Reduced recoil, especially in calcified lesions
• Precise placement due to controlled expansion
• High radial strength, ensuring long-term patency
• Lower risk of vessel damage, due to predictable deployment

These characteristics make balloon-expandable stents the preferred choice for renal and coronary stenting, where accuracy and stability are critical. As the global burden of coronary artery diseases continues to rise, the demand for balloon-expandable stents is expected to grow at a rapid pace.

Material Analysis: Cobalt Chromium (CoCr) Remains the Fastest-Growing Segment

Based on material, the market is segmented into:

• Metallic materials
  • Cobalt Chromium (CoCr)
  • Platinum Chromium
  • Nickel Titanium (Nitinol)
  • Stainless Steel
• Polymer-based materials

Among these, Cobalt Chromium (CoCr) dominated as the fastest-growing material segment in 2023. CoCr stents are preferred because they deliver superior performance compared to traditional stainless steel stents. Key advantages include:

• Higher radiopacity, enhancing visibility during angioplasty
• Superior radial strength, enabling reduced strut thickness
• Improved biocompatibility, lowering the risk of thrombosis
• Minimal elastic recoil, ensuring precise vessel expansion

The combination of mechanical durability, thin-strut design, and enhanced imaging capabilities positions CoCr stents as a top choice for next-generation balloon-expandable stents. As minimally invasive cardiovascular interventions continue gaining traction, the cobalt chromium segment is expected to maintain strong growth.

End User Analysis: Hospitals Dominate the Market

The vascular stents market is segmented into:

• Hospitals
• Cardiac centers

In 2023, hospitals accounted for the largest and fastest-growing share, driven by the increasing number of hospitalizations related to cardiovascular ailments. Rising cases of CAD, strokes, and heart attacks have significantly increased the demand for stent procedures performed in hospital settings.

For example, data from the Centers for Disease Control and Prevention (CDC) revealed that 6.4% of U.S. emergency department visits in 2021 involved coronary artery disease, ischemic heart disease, or myocardial infarction. As hospitals perform the majority of angioplasty and PCI procedures, they remain the primary end users of vascular stents. This trend is expected to continue through 2029 due to rising cardiovascular disease burden and expanding hospital infrastructure worldwide.

Request Sample Report

Regional Analysis: North America Leads the Global Market

The global vascular stents market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

In 2023, North America dominated the global vascular stents market, attributed to the high prevalence of heart diseases, advanced healthcare systems, and strong adoption of minimally invasive cardiology procedures. In 2022, heart disease caused 702,880 deaths in the U.S., accounting for 1 in every 5 fatalities, according to the CDC. This rising disease burden significantly boosts the need for vascular stents.

Additionally, the region benefits from early adoption of innovative stent technologies, significant healthcare spending, well-established cardiac care centers, and a strong presence of leading market players, all contributing to its dominant market position.

Key Market Players

Major companies operating in the vascular stents market include:

• Medtronic Plc (Ireland)
• Abbott Laboratories (US)
• Boston Scientific Corporation (US)
• B. Braun SE (Germany)
• Terumo Corporation (Japan)
• Biotronik SE & Co. KG (Germany)
• Shanghai MicroPort Medical Group (China)
• Meril Life Sciences Pvt. Ltd (India)
• Sahajanand Medical Technologies Ltd (India)
• Becton, Dickinson and Company (US)
• W.L. Gore & Associates (US)
• Cordis Corporation (US)
• Stryker Corporation (US)
• LifeTech Scientific (China)
• Translumina (Germany)
• Lepu Medical (China)
• Elixir Medical (US)
• Endologix LLC (US)
• Biosensors International (Singapore)
• Cook Medical (US)
• iVascular (Spain)
• OrbusNeich Medical (China)
• Alvimedica (Turkey)

These players focus on strategic collaborations, product innovations, regulatory approvals, and geographical expansion to strengthen their market footprint.